Bolt Biotherapeutics (BOLT) Competitors

Bolt Biotherapeutics (NASDAQ:BOLT) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.

Which has stronger valuation and earnings, BOLT or FBIO?

Fortress Biotech has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.88M	5.37	-$69.20M	-$1.83	-0.61
Fortress Biotech	$84.51M	0.40	-$60.64M	-$8.22	-0.21

Do insiders and institutionals have more ownership in BOLT or FBIO?

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 28.4% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 33.4% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in BOLT or FBIO?

Fortress Biotech received 243 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 68.38% of users gave Bolt Biotherapeutics an outperform vote while only 64.86% of users gave Fortress Biotech an outperform vote.

Company	Underperform	Outperform
Bolt Biotherapeutics	Outperform Votes 80 68.38%	Underperform Votes 37 31.62%
Fortress Biotech	Outperform Votes 323 64.86%	Underperform Votes 175 35.14%

Is BOLT or FBIO more profitable?

Fortress Biotech has a net margin of -74.12% compared to Bolt Biotherapeutics' net margin of -878.58%. Bolt Biotherapeutics' return on equity of -51.18% beat Fortress Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-878.58%	-51.18%	-37.81%
Fortress Biotech	-74.12%	-770.86%	-32.87%

Does the media refer more to BOLT or FBIO?

In the previous week, Fortress Biotech had 3 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 4 mentions for Fortress Biotech and 1 mentions for Bolt Biotherapeutics. Fortress Biotech's average media sentiment score of 0.94 beat Bolt Biotherapeutics' score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, BOLT or FBIO?

Bolt Biotherapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.

Do analysts recommend BOLT or FBIO?

Bolt Biotherapeutics currently has a consensus target price of $7.00, indicating a potential upside of 530.63%. Fortress Biotech has a consensus target price of $30.00, indicating a potential upside of 1,614.29%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Fortress Biotech beats Bolt Biotherapeutics on 13 of the 17 factors compared between the two stocks.